Blueweave
Blood Screening Market Report

Blood Screening Market Report

Global Blood Screening Market, By Product And Services (Reagents And Kit, NAT Reagents And Kit[Enzyme And Polymerases Standards And Controls, Probes And Primes, Buffers Nucleotides, And Solutions, Labeling And Detection Reagents], ELISA Reagents And Kit[Immunosorbents, Controls, Conjugates, Substrates, Sample Diluents And Washing Solutions], Other Reagents And Kits, Instruments, Outright Purchase, Rental Purchase, software And Services); By Technology (Nucleic Acid Testing [Transcription Mediated Amplification, Real-Time Polymerase Chain Reaction], Enzyme-Linked Immunosorbent Assay [Chemiluminescence Immunoassay, Fluorescent Immunoassay, Colorimetric Immunoassay], Rapid Test, Western Blot Assay, Next-Generation Screening); By End-User (Hospitals, Blood Banks), By Region (North America, Europe, The Asia-Pacific, The Middle East & Africa, And Latin America) Trend Analysis, Competitive Market Share & Forecast, 2017-2027

  • Published Date: May 2021
  • Report ID: BWC20343
  • Available Format: PDF
  • Page: 161

Report Overview

Global Blood Screening Market- Industry Trends & Forecast Report 2027


The global blood screening market was worth USD 1.8 billion in 2020 and is further projected to reach USD 4.0 billion by 2027, at a CAGR of 11.1% during the forecast period (2021-2027). This sharp rise can be attributed to the increasing awareness about blood donations, increased frequency in the occurrence of various infectious diseases, as well as programs undertaken by government and non-government organizations. Blood screening methods are used to identify various infectious diseases such as HBV (hepatitis B), HCV (hepatitis C), HIV1 (Human immunodeficiency virus), COVID-19, HIV2, and others in donated blood in order to ensure the safety of the process of blood transfusion.

 

                                      

Source: Blue Weave Consulting

Global Blood Screening Market Overview

To ensure healthy blood units, essential procedures must be followed during the examination of donated blood and the separation of blood and blood components. Depending on the outcome of the tests, they are either issued for therapeutic use or manufacturing, or they are disposed of. Different procedures, reagents, kits, instruments, and software are used to conduct laboratory tests on blood samples obtained during donation. All blood sample tests are performed and recorded in well-equipped laboratories using tried-and-true procedures. All blood samples, donations, and components are marked with the appropriate label to ensure proper identification throughout the testing process. Strong guidelines are in place to avoid errors that lead to dangerous blood transfusions.

Global Blood Screening Market Trend

Growth Drivers

Increased Awareness for Blood Donations

Donation and pre-transfusion research have become more common as a result of efforts by numerous organizations and governments. According to the WHO, approximately 108 million blood donations are collected annually worldwide. Half of these blood donations are received in poor countries with less than 20% of the population. Rising recognition and high demand for safe blood necessitate the development of suitable testing technologies, reagents, kits, and other items to build opportunities for developing countries. Furthermore, the rate of testing for hepatitis B, hepatitis C, and viruses has nearly doubled in many countries, generating an ever-increasing demand for blood testing kits for different diseases, which is creating opportunities in the global blood screening industry. To encourage volunteers, the WHO had also set a goal to provide safe access to blood worldwide. Similarly, the Australian Red Cross launched a project called "First Blood: Overcoming Donor Fear," which encourages people to donate blood by providing a toolkit to help first-time donors overcome their anxiety. These programs raise voluntary investments and are expected to shift the demand over the forecast period.

Growing Frequency of Newer Pathogens

In recent years, there has been an unexpected increase in the number of novel infections caused by bacteria, viruses, fungi, zoonotic diseases (diseases transmitted by animals), and so on. Additionally, various pathogens also attack the living organisms through various vectors (virus in most cases). In addition, comprehensive R&D is being promoted continually to classify the characteristics of pathogens for diagnosing their presence in the blood. A physician will usually recommend a blood test to patients in order to detect any serious diseases or complications in advance. To prioritize R&D in public health emergency contexts, recently, the WHO is constantly focusing on the high risk of various potential pathogens and diseases like COVID-19, Crimean-Congo hemorrhagic fever, Ebola virus disease, and Marburg virus disease, Lassa fever, Middle East respiratory syndrome coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome (SARS), Nipah and henipaviral diseases, Rift Valley fever, Zika, and so on.

Restraints

High Cost and Unreliable Results are Expected to Hinder the Market Growth

The shortage of trained professionals with less knowledge has been a major challenge to this market. Moreover, blood tests that involve direct contact with the body may be inconvenient for patients and pose a significant risk of infection transmissions, such as Hepatitis A, and B, or HIV. Also, some blood testing devices are very costly, and they necessitate the use of sensors every month. Additionally, since certain blood test kits are inaccurate and can generate an incorrect result, self-testing puts the patient's life at risk. These are some factors that are impeding the growth of the global blood screening market.

Impact of COVID-19

The COVID-19 epidemic has created havoc on the global economy. Due to high levels of infection and the detrimental effects on public health systems, many countries have had to tighten national closures, impacting supply chains in manufacturing, commerce, and other related services in particular. The world is currently searching for new ways for independent laboratories to extend their research. However, curfews and lockdown worldwide have almost halted the blood donations, decreased/canceled collection drives, diminished the demand for donated blood, and has adversely affected the growth of the blood screening market during the forecasted period globally. However, since the lockdown restrictions are being eased by the governments of different countries, the number of blood donors has increased.

Global Blood Screening Market: By Product and Services

The product and services category broadly consists of reagents and kits, NAT reagents and kits, ELISA reagents and kits, other reagents and kits, instruments, outright purchase, rental purchase, and software and services. Among these, the reagents and kits segment has dominated the market. The large share of this category is mainly due to the frequent utilization of reagents and kits, increased transfusion-related screenings, increased blood donations, and the increasing incidence of chronic or infectious diseases. In addition, reagents are cost-effective for customers and offer a high return on retail investment.

The high cost and reusable nature of the Instruments can hinder the growth of the blood test market. However, following consumer acceptance for the launch of instruments, the growing success of the instrument segment cannot be ignored. For instance, the FDA (Food and Drug Administration) approved Roche’s Cobas Zika donor screening test for the Zika virus. This can prevent the spread of the Zika virus in the U.S. through blood donations.

Global Blood Screening Market: By Technology

Based on the technology the global blood screening market is fragmented into nucleic acid testing, enzyme-linked immunosorbent assay, rapid test, western blot assay, next-generation screening.

The nucleic acid amplification test (NAT) is growing at the fastest rate due to its high sensitivity and specificity for viral nucleic acid. The test can detect nucleic acid earlier than other screening techniques and thus, shrinks the window period of HBV (hepatitis B), HCV (hepatitis C), and HIV (human immune deficiency virus) infections.

 

                                       

                                                                                     Source: Blue Weave Consulting

 

Global Blood Screening Market: By End-User

Based on end-user, the global blood screening market is broadly classified into two categories--hospitals and blood banks. Both blood banks, as well as hospitals, follow almost a similar channel to procure blood and then making it available to a patient in need. People may willingly donate blood, which is usually accompanied by the issuance of a donor card, which can be used in the future to obtain any form of blood required by the patient. Following COVID-19, all blood banks and hospitals are under intense pressure to supply blood for safe transfusions in COVID patients.

Global Blood Screening Market: Regional Insights

Geographically, the global blood screening market is categorized into North America, Europe, the Asia-Pacific, the Middle East & Africa, And Latin America. North America accounted for the largest market share, followed by Europe. Factors such as the evolving demand for donated blood, the increasing number of blood donations, the high prevalence of infectious diseases, and the high prevalence of novel pathogens, the presence of high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players in the region are some of the driving factors leading to the growth of the blood screening market in North America. Furthermore, the Asia Pacific region is growing at the fastest rate in the global blood screening market, owing to rising patient affordability, increased awareness about blood donation, and increased emphasis of major industry players on emerging countries in the region.

                                      

Competitive Landscape

The high growth potential of the global blood screening market has drawn several new entrants, creating a lucrative opportunity. The emergence of new entrants has also resulted in healthy competition among long-established service providers in the industry.

The market seems to be fragmented having the key players namely Grifols, F. Hoffmann-La Roche AG, Abbott Laboratories, BioMérieux, Bio-Rad Laboratories, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific Inc., Ortho Clinical Diagnostics, Inc., Becton, Dickinson and Company, DiaSorin, GFE, Trinity Biotech, Merck Millipore, GE Healthcare, Perkin Elmer, and Bio-Techne Corporation.

 

Recent Development 

  • In April 2020, Abbott Laboratories (U.S.) received EUA (emergency use authorization) from the FDA for its chemiluminescent microparticle immunoassay (CMIA).

  • In April 2020, Bio-Rad Laboratories, Inc. (U.S.) received EUA (emergency use authorization) for its modified ELISA—The Platelia SARS-CoV-2 Total Ab assay, which measures antibodies.

 

Attribute Details
Years Considered Historical data – 2017-2020
Base Year – 2020
Forecast – 2021 – 2027
Facts Covered Revenue in USD Billion
Market Coverage U.S., Canada, Germany, U.K., France, Italy, Spain, Japan, China, India, Australia, Brazil, Mexico, South Africa, Saudi Arabia, U.A.E.
Product/Service Segmentation By Products and Services, By Technology , By End-User, and By Region
Key Players Abbott Laboratories, Becton-Dickson and Company, Bio-Rad Laboratories, Danaher Corporation, F. Hoffman-La Roche, Ltd., Grifols, Ortho Clinical Diagnostic, Siemens Helthineers, SOFINA s. a.  (Biomérieux), Thermo Fisher Scientific

  

By Product and Services

  1. Reagents and Kit

NAT Reagents and Kit

  • Enzyme and Polymerases
  • Standards and Controls
  • Probes and Primes
  • Buffers, Nucleotides, and Solutions
  • Labeling and Detection Reagents

2. ​Elisa Reagents and Kits

  • Immunosorbents
  • Controls
  • Conjugates
  • Substrates
  • Sample Diluents and Wash Solutions

3. Other Reagents and Kits

4. Instruments

5. Outright Purchae

6. Rental purchase

7. Software and services

By Technology

1. Nucleic Acid Testing

  •  Transcription Mediated-Amplification
  • Real-Time Polymerase Chain Reaction

2. Enzyme-Linked Immunosorbent Assay

  • Chemiluminescence Immunoassay
  • Fluorescent Immunoassay
  • Colorimetric Immunoassays

3. Rapid Tests

4.Western Blot Assay

5.Next-Generation Sequencing

By End-User

  1. Blood Banks
  2. Hospitals

By Region

1. North America

  1. U.S.
  2. Canada

2. Europe

  1. Germany
  2. U.K.
  3. France
  4. Italy
  5. Spain
  6. Rest of Europe

3. Asia Pacific

  1. China
  2. Japan
  3. India
  4. Australia
  5. Rest of Asia-Pacific

4. Latin America

  1. Brazil
  2. Mexico
  3. Rest of Latin America

5. Middle East and Africa

  1. South Africa
  2. Saudi Arabia
  3. U.A.E.
  4. Rest of MEA

 

1.    Research Framework

1.1. Research Objective

1.2. Product Overview

1.3. Market Segmentation

2.    Research Methodology

2.1. Qualitative Research

2.1.1.   Primary & Secondary Research

2.2. Quantitative Research

2.3. Market Breakdown & Data Triangulation

2.3.1.   Primary & Secondary Research Application

2.3.2.   Secondary Research

2.3.3.   Primary Research

2.4. Breakdown of Primary Research Respondents, By Region

2.5. Assumption & Limitation

3.    Executive Summary

4.    Global blood screening Market Insights

4.1. Industry Value Chain Analysis

4.2. DROC Analysis

4.2.1.   Growth Drivers

4.2.2.   Restraints

4.2.3.   Opportunities

4.2.4.   Challenges

4.3. Recent Development/Technological Advancements

4.4. Porter’s Five Forces Analysis

4.4.1.   Bargaining Application of Suppliers

4.4.2.   Bargaining Application of Buyers

4.4.3.   Threat of New Entrants

4.4.4.   Threat of Substitutes

4.4.5.   Intensity of Rivalry

5.    Global blood screening Market Overview

5.1. Market Size & Forecast by Value, 2017-2027

5.1.1.   By Value (USD Million)        

5.2. Market Share & Forecast

5.2.1.   By Product And Services 

5.2.1.1.        Reagents and Kit

5.2.1.2.       NAT Reagents and Kit

5.2.1.2.1.           Enzyme and Polymerases

5.2.1.2.2.           Standards and Controls

5.2.1.2.3.           Probes and Primes

5.2.1.2.4.           Buffers, Nucleotides and Solutions

5.2.1.2.5.           Labelling and Detection Reagents

5.2.1.3.       Elisa Reagents and Kits

5.2.1.3.1.           Immunosorbents

5.2.1.3.2.           Controls

5.2.1.3.3.           Conjugates

5.2.1.3.4.           Substrates

5.2.1.3.5.           Sample Diluents and Wash Solutions

5.2.1.4.       Other Reagents and Kits

5.2.1.5.       Instruments

5.2.1.6.       Outright Purchase

5.2.1.7.       Rental purchase

5.2.1.8.       Software and Services

 

5.2.2.   . By Technology

5.2.2.1.       Nucleic Acid Testing

5.2.2.1.1.           Transcription Mediated-Amplification

5.2.2.1.2.           Real Time Polymerase Chain Reaction

5.2.2.2.       Enzyme Linked Immunosorbent Assay

5.2.2.2.1.           Chemiluminescence Immunoassay

5.2.2.2.2.           Fluorescent Immunoassay

5.2.2.2.3.           Colorimetric Immunoassays

5.2.2.3.       Rapid Tests

5.2.2.4.       Western Blot Assay

5.2.2.5.       Next Generation Sequencing

5.2.3.   By End User

5.2.3.1.       Blood Banks

5.2.3.2.       Hospitals

5.2.4.   By Region

5.2.4.1.       North America

5.2.4.1.1.           U.S.

5.2.4.1.2.           Canada

5.2.4.2.       Europe

5.2.4.2.1.           Germany

5.2.4.2.2.           U.K.

5.2.4.3.       Asia Pacific

5.2.4.3.1.           China

5.2.4.3.2.           Japan

5.2.4.3.3.           India

5.2.4.4.       Latin America

5.2.4.4.1.           Brazil

5.2.4.4.2.           Mexico

5.2.4.5.       Middle East and Africa

5.2.4.5.1.           South Africa

 

 

 

6.    North America Blood Screening Market

6.1. Market Size & Forecast by Value, 2017-2027

6.1.1.             By Value (USD Million)

6.2. Market Share & Forecast

6.2.1.             By Product and Services

6.2.2.             By Technology

6.2.3.             By End User

6.2.4.             By Country

6.2.4.1.               U.S.

6.2.4.2.               Canada

 

7.    Europe Blood Screening Market

7.1. Market Size & Forecast by Value, 2017-2027

7.1.1.             By Value (USD Million)

7.2. Market Share & Forecast

7.2.1.             By Product and Services

7.2.2.             By Technology

7.2.3.             By End User

7.2.4.             By Country

7.2.4.1.               Germany

7.2.4.2.               U.K.

 

8.    Asia pacific Blood Screening Market

8.1. Market Size & Forecast by Value, 2017-2027

8.1.1.             By Value (USD Million)

8.2. Market Share & Forecast

8.2.1.             By Product and Services

8.2.2.             By Technology

8.2.3.             By End User

8.2.4.             By Country

8.2.4.1.1.          China

8.2.4.1.2.          Japan

8.2.4.1.3.          India

 

9.    Latin America Blood Screening Market

9.1. Market Size & Forecast by Value, 2017-2027

9.1.1.             By Value (USD Million)

9.2. Market Share & Forecast

9.2.1.             By Product and Services

9.2.2.             By Technology

9.2.3.             By End User

9.2.4.             By Country

9.2.4.1.1.        Brazil

9.2.4.1.2.        Mexico

 

 

 

10.Middle east and Africa  Blood Screening Market

10.1.     Market Size & Forecast by Value, 20xx-20xx

10.1.1.          By Value (USD Million)

10.2.     Market Share & Forecast

10.2.1.          By Product and Services

10.2.2.          By Technology

10.2.3.          By End User

10.2.4.          By Country

10.2.4.1.1.     South Africa

 

 

11.Competitive Landscape

11.1.     Market Share Analysis

11.2.     Competitive Scenario

11.3.     Competitive Leadership Mapping

12.Impact of Covid-19 across Industry

13.Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

13.1.     Abbott Laboratories

13.2.     Becton-Dickson and Company

13.3.     Bio-Rad Laboratories

13.4.     Danaher Corporation

13.5.     F. Hoffman-La Roche, Ltd.

13.6.     Grifols

13.7.     Ortho Clinical Diagnostic

13.8.     Siemens Helthineers

13.9.     SOFINA s.a (Biomérieux)

13.10.  Thermo Fisher Scientific

14.Key Strategic Recommendations

 

*Financial details of unlisted companies will be available as per data availability in final deliverable

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

List of Figures

 

Fig: Global Blood Screening Segmentation

Fig: Global Blood Screening Market Value Chain Analysis

Fig: Company Market Share Analysis, 2020

Fig: Global Blood Screening Market Size, By Value (USD Million), 2017-2027

Fig: Global Blood Screening Market Share (%), By Product, and Services Type, By Value, 2017-2027

Fig: Global Blood Screening Market Share (%), By Technology, By Value, 2017-2027

Fig: Global Blood Screening Market Share (%), By End User, By Value, 2017-2027

Fig: Global Blood Screening Market Share (%), By Country, By Value, 2017-2027

Fig: North America Blood Screening Market Size, By Value (USD Million), 2017-2027

Fig: North America Blood Screening Market Share (%), By Product, and Services Type, By Value, 2017-2027

Fig: North America Blood Screening Market Share (%), By Technology, By Value, 2017-2027

Fig: North America Blood Screening Market Share (%), By End User, By Value, 2017-2027

Fig: North America Blood Screening Market Share (%), By Country, By Value, 2017-2027

Fig: Europe Blood Screening Market Size, By Value (USD Million), 2017-2027

Fig: Europe Blood Screening Market Share (%), By Product, and Services Type, By Value, 2017-2027

Fig: Europe Blood Screening Market Share (%), By Technology, By Value, 2017-2027

Fig: Europe Blood Screening Market Share (%), By End User, By Value, 2017-2027

Fig: Europe Blood Screening Market Share (%), By Country, By Value, 2017-2027

Fig: The Asia-Pacific Blood Screening Market Size, By Value (USD Million), 2017-2027

Fig: The Asia-Pacific Blood Screening Market Share (%), By Product, and Services Type, By Value, 2017-2027

Fig: The Asia-Pacific Blood Screening Market Share (%), By Technology, By Value, 2017-2027

Fig: The Asia-Pacific Blood Screening Market Share (%), By End User, By Value, 2017-2027

Fig: The Asia-Pacific Blood Screening Market Share (%), By Country, By Value, 2017-2027

Fig:  Latin America Blood Screening Market Size, By Value (USD Million), 2017-2027

Fig:  Latin America Blood Screening Market Share (%), By Product, and Services Type, By Value, 2017-2027

Fig:  Latin America Blood Screening Market Share (%), By Technology, By Value, 2017-2027

Fig:  Latin America Blood Screening Market Share (%), By End User, By Value, 2017-2027

Fig:  Latin America Blood Screening Market Share (%), By Country, By Value, 2017-2027

Fig: The Middle East & Africa Blood Screening Market Size, By Value (USD Million), 2017-2027

Fig: The Middle East & Africa Blood Screening Market Share (%), By Product, and Services Type, By Value, 2017-2027

Fig: The Middle East & Africa Blood Screening Market Share (%), By Technology, By Value, 2017-2027

Fig: The Middle East & Africa Blood Screening Market Share (%), By End User, By Value, 2017-2027

Fig: The Middle East & Africa Blood Screening Market Share (%), By Country, By Value, 2017-2027

 

List of Tables

Table: North America Blood screening Market Size, By Product and Services Type, By Value (USD Million), 2017-2027                                                    

Table: North America Blood screening Market Size, By Technology, By Value (USD Million), 2017-2027                                                         

Table: North America Blood screening Market Size, By End User, By Value (USD Million), 2017-2027                                                       

Table: Europe Blood screening Market Size, By Product and Services Type, By Value (USD Million), 2017-2027                                                  

Table: Europe Blood screening Market Size, By Technology, By Value (USD Million), 2017-2027                                                      

Table: Europe Blood screening Market Size, By End User, By Value (USD Million), 2017-2027                                               

Table: the Asia-Pacific Blood screening Market Size, By Product and Services Type, By Value (USD Million), 2017-2027                                                    

Table: the Asia-Pacific Blood screening Market Size, By Technology, By Value (USD Million), 2017-2027                                                         

Table: the Asia-Pacific Blood screening Market Size, By End User, By Value (USD Million), 2017-2027                                                      

Table: Latin America Blood screening Market Size, By Product and Services Type, By Value (USD Million), 2017-2027                                                    

Table: Latin America Blood screening Market Size, By Technology, By Value (USD Million), 2017-2027                                                    

Table: Latin America Blood screening Market Size, By End User, By Value (USD Million), 2017-2027                                                

Table: The Middle-East & Africa Blood screening Market Size, By Product and Services Type, By Value (USD Million), 2017-2027                                                    

Table: The Middle-East & Africa Blood screening Market Size, By Technology, By Value (USD Million), 2017-2027                                                  

Table: The Middle-East & Africa Blood screening Market Size, By End User, By Value (USD Million), 2017-2027                                                  

Table: Abbott Laboratories Financial Analysis

Table: Abbott Laboratories Business Overview

Table: Becton-Dickson and Company Financial Analysis

Table: Becton-Dickson and Company Business Overview

Table: Bio-Rad Laboratories Financial Analysis

Table: Bio-Rad Laboratories Business Overview

Table: Danaher Corporation Financial Analysis

Table: Danaher Corporation Business Overview

Table: F. Hoffman-La Roche, Ltd. Financial Analysis

Table: F. Hoffman-La Roche, Ltd. Business Overview

Table: Grifols Financial Analysis

Table: Grifols Business Overview

Table: Ortho Clinical Diagnostic Financial Analysis

Table: Ortho Clinical Diagnostic Business Overview

Table: Siemens Diagnostic Business Analysis

Table: Siemens Diagnostic Business Overview

Table: SOFINA sea (Biomérieux)Financial Analysis

Table: SOFINA sea (Biomérieux)Business Overview

Table: Thermo Fisher Scientific Financial Analysis

Table: Thermo Fisher Scientific Business Overview

 

 

Market Segmentation

By Product and Services

  1. Reagents and Kit

NAT Reagents and Kit

  • Enzyme and Polymerases
  • Standards and Controls
  • Probes and Primes
  • Buffers, Nucleotides, and Solutions
  • Labeling and Detection Reagents

2. ​Elisa Reagents and Kits

  • Immunosorbents
  • Controls
  • Conjugates
  • Substrates
  • Sample Diluents and Wash Solutions

3. Other Reagents and Kits

4. Instruments

5. Outright Purchae

6. Rental purchase

7. Software and services

By Technology

1. Nucleic Acid Testing

  •  Transcription Mediated-Amplification
  • Real-Time Polymerase Chain Reaction

2. Enzyme-Linked Immunosorbent Assay

  • Chemiluminescence Immunoassay
  • Fluorescent Immunoassay
  • Colorimetric Immunoassays

3. Rapid Tests

4.Western Blot Assay

5.Next-Generation Sequencing

By End-User

  1. Blood Banks
  2. Hospitals

By Region

1. North America

  1. U.S.
  2. Canada

2. Europe

  1. Germany
  2. U.K.
  3. France
  4. Italy
  5. Spain
  6. Rest of Europe

3. Asia Pacific

  1. China
  2. Japan
  3. India
  4. Australia
  5. Rest of Asia-Pacific

4. Latin America

  1. Brazil
  2. Mexico
  3. Rest of Latin America

5. Middle East and Africa

  1. South Africa
  2. Saudi Arabia
  3. U.A.E.
  4. Rest of MEA

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe.